Scinai Immunotherapeutics (SCNI) Profit After Tax (2014 - 2026)

Scinai Immunotherapeutics (SCNI) has 13 years of Profit After Tax data on file, last reported at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 57.33% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$8.5 million (down 194.22% YoY), and the FY2025 full-year result was -$11.0 million, down 328.54% from the prior year.
• Profit After Tax eased to -$2.5 million in Q1 2026, from -$2.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $10.5 million in Q3 2024 to a low of -$6.5 million in Q4 2022.
• A 5-year average of $234466.7 and a median of -$1.6 million in 2025 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax soared 242.02% in 2023 and plunged 194.53% in 2025, its largest moves.
• Tracing SCNI's Profit After Tax over 5 years: stood at -$6.5 million in 2022, then surged by 59.9% to -$2.6 million in 2023, then increased by 14.13% to -$2.2 million in 2024, then climbed by 1.57% to -$2.2 million in 2025, then fell by 12.39% to -$2.5 million in 2026.
• Business Quant data shows SCNI's Profit After Tax at -$2.5 million in Q1 2026, -$2.2 million in Q2 2025, and -$1.6 million in Q1 2025.